Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Tuesday, May 9, 2017

Pregnant Women with Relapsing MS Can Use Copaxone Without Harming Baby, Study Indicates


                                                                  
  
Click here to receive MS news via e-mail



Babies of women with relapsing multiple sclerosis (RMS) who receive daily injections of Copaxone (glatiramer acetate) while pregnant carry the same risk of developing birth defects as babies as a whole, according to a study by the therapy’s developer, Teva Pharmaceutical Industries.

The findings can help doctors counsel and treat women with RMS who become pregnant. The study, “Pregnancy Outcomes From The Branded Glatiramer Acetate Pregnancy Database,” was published in the International Journal of MS Care.
Copaxone is a synthetic protein that simulates the production of myelin, a substance that protects nerve fibers in the brain and spinal cord and that is degraded in MS. The drug also suppresses the immune system by preventing T-cells — a type of immune system cells — from damaging myelin in a process called demyelination.
There have been no well-controlled studies in pregnant women’s use of Copaxone until now.
Teva decided to investigate whether babies born to MS patients treated with Copaxone while pregnant were at higher risk of having a congenital problem than babies as a whole.
Researchers compared data on babies born to Copaxone-treated MS patients with data on babies born to healthy women.


MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

No comments: